CS-101’s early results are encouraging—but the evidence is still small

CorrectSequence Therapeutics’ CS-101 has delivered striking early results in transfusion-dependent beta-thalassemia, but it is important to separate published clinical evidence from broader company-reported updates.

The peer-reviewed evidence currently covers five people in an early-phase CS-101 study. The company’s claim that more than 30 patients have been treated across four continents, with 100% achieving transfusion independence or freedom from vaso-occlusive crises, combines CS-101 with CS-206, a separate sickle-cell candidate. It is not a completed pivotal-trial result for CS-101 alone. 113

What the clinical results show

In the phase 1 study in China (NCT06024876), five patients with transfusion-dependent beta-thalassemia received their own CD34+ blood-forming stem and progenitor cells after the cells had been edited outside the body with CS-101. The goal was to restore production of fetal haemoglobin, or HbF. 1

The published report found that all five patients stopped needing red-blood-cell transfusions. Median follow-up was 23 months, with median neutrophil and platelet engraftment times of 16 and 25 days, respectively. 1

CorrectSequence has also reported treatment of additional patients outside China: three people with beta-thalassemia from Laos, Malaysia and Pakistan, and one person with sickle-cell disease from Nigeria. The company said the three beta-thalassemia patients remained transfusion-independent at a median follow-up of 17.5 months. 13

For the Nigerian sickle-cell patient, the company reported neutrophil engraftment on day 13 and platelet engraftment on day 21. It said haemoglobin increased from 7.7 g/dL before treatment to 12.9 g/dL at month 3, HbF rose above 60%, and no vaso-occlusive crises occurred through 15.5 months of follow-up. These are highly encouraging findings, but they come from one patient and cannot yet establish effectiveness across the wider sickle-cell population. 11

How CS-101 is designed to work

CS-101 is an autologous, ex vivo cell therapy: clinicians collect a patient’s own CD34+ cells, edit them in the laboratory, then return them after conditioning treatment.

The therapy alters BCL11A-binding motifs in the promoters of the HBG1 and HBG2 genes. BCL11A normally helps suppress gamma-globin production after birth. Reducing that repression is intended to switch fetal haemoglobin back on. Higher HbF can compensate for defective beta-globin in beta-thalassemia and can reduce the sickling process in sickle-cell disease. 13

CorrectSequence calls its platform transformer Base Editor, or tBE. It uses a dual-guide-RNA “lock-and-key” design and is intended to make specific base substitutions rather than cutting both strands of DNA at the target site.

Why the safety approach matters—and what is not yet known

The absence of an intended double-strand DNA break is a meaningful design feature. Nuclease-based editing systems such as CRISPR-Cas9 and Cas12a typically create such breaks, which can lead to insertions or deletions, large deletions, chromosomal rearrangements or translocations. DNA breaks may also trigger a cellular DNA-damage response, including p53 signalling.

A base-editing approach is therefore designed to lower some of those risks. But a design advantage is not the same as a proven long-term clinical safety advantage. A report of no detectable off-target mutations means none were found using the particular assays and detection thresholds used; it does not rule out rare off-target edits, structural variants, clonal expansion or later malignancy risk.

Long-term follow-up in larger and more diverse groups will be essential for determining genomic safety.

Does CS-101 outperform other gene-editing treatments?

There is no identified randomized or head-to-head clinical trial comparing CS-101 or tBE directly with Cas9- or Cas12a-based therapies. As a result, claims of greater precision, faster engraftment, less p53 activation or reduced chromosomal damage remain mechanistic, preclinical or cross-study observations—not definitive comparative clinical evidence.

The day-13 neutrophil engraftment reported in the Nigerian sickle-cell case is favourable, but a single case cannot demonstrate that tBE produces consistently faster or more durable engraftment than competing editing platforms. 11

Likewise, HbF above 60% could be clinically important for sickle-cell disease, yet the current reported sickle-cell evidence is far too limited to define an expected response rate or long-term benefit. 11

How diverse is the patient evidence?

The early published CS-101 cohort was based in China. Subsequent company updates describe patients from Laos, Malaysia and Pakistan with beta-thalassemia, as well as a Nigerian patient with sickle-cell disease. 13

That geographic and genetic breadth is encouraging because beta-haemoglobin disorders involve many disease-causing variants worldwide. Still, a handful of patients from different backgrounds is not enough to establish consistent results across populations. The company’s larger, more than 30-patient figure includes both CS-101 and CS-206, so it should not be interpreted as a CS-101-only efficacy dataset. 13

What comes next for CS-101

CS-101 entered early clinical study for beta-thalassemia, with the five-patient phase 1 report registered as NCT06024876. 1

The company reported treating its first overseas beta-thalassemia patient in July 2024. 12 It has also reported a first sickle-cell patient treated in 2025, although the ClinicalTrials.gov record identifies CS-206, rather than CS-101, as the sickle-cell clinical candidate. 514

A phase 2 trial of CS-101 in beta-thalassemia major, NCT07489196, is registered as an open-label, single-arm study and listed as not yet recruiting. 3

CorrectSequence has described CS-101 as being at a “pivotal clinical trial stage.” However, the public registry labels the newly listed study as phase 2. Based on the public record, “pivotal” should be understood as the company’s characterization, rather than confirmation of an active conventional registrational phase 3 trial. 312

Beyond haemoglobin disorders, the company has said it aims to apply its platform to metabolic and cardiovascular conditions, including APOC3 base editing for hyperlipidaemia. 1013

Bottom line

CS-101 has a clinically supported mechanism for reactivating fetal haemoglobin and has produced notable early beta-thalassemia outcomes, including transfusion independence in a five-patient peer-reviewed study. The wider company-reported experience suggests potential across multiple genetic and geographic backgrounds.

But the clinical dataset remains small, largely single-arm and partly company-reported. It does not yet establish superior performance over other editing technologies, durable effectiveness across broad populations or long-term genomic safety. Those are the questions larger studies and extended follow-up will need to answer.